AusperBio completes enrolment in Phase III AUSHINE trial for chronic hepatitis B

AusperBio has announced the completion of patient enrolment in its Phase III AUSHINE trial evaluating AHB-137 for chronic hepatitis B (CHB). The multicentre, randomised, double-blind study is assessing the safety and efficacy of AHB-137 injections in HBeAg-negative CHB patients receiving nucleos(t)ide analogue therapy.

CHB remains a major global health concern, with nearly 254 million people affected and 1.2 million new infections annually, according to WHO’s 2024 report. AHB-137 is an unconjugated antisense oligonucleotide developed via AusperBio’s Med-Oligo platform, designed to achieve a functional cure by combining immune reactivation, targeted HBsAg suppression, and inhibition of viral DNA replication.

Having completed Phase I globally and multiple Phase II studies, the Phase III trial enrolled over 570 patients ahead of schedule, marking a key milestone in AusperBio’s efforts to deliver a potential functional cure for HBV infection.

29-12-2025